Cargando…

Dose Escalating and Bioavailability Phase 1 Studies Assessing Safety and Tolerability and Pharmacokinetics of Tildacerfont, a Small-Molecule CRF1 Receptor Antagonist

Background: Tildacerfont (SPR001; LY2371712), a second generation, potent, selective, nonsteroidal, oral small-molecule antagonist of corticotropin-releasing factor type-1 (CRF1) receptors in the pituitary gland, is in late stage development as a potential treatment for adults with congenital adrena...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barnes, Chris, Offman, Elliot, Darago, Nora, Moriarty, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Adrenal
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089947/ http://dx.doi.org/10.1210/jendso/bvab048.135

Ejemplares similares

Changes in Adrenal and Gonadal Androgens After 14-Day Treatment With CRF1 Receptor Antagonist, Crinecerfont (NBI-74788), in Men With Classic 21-Hydroxylase Deficiency
por: He, Xin, et al.
Publicado: (2021)

SAT286 Effect of Tildacerfont On Gonadotropins And Testicular Steroidogenesis In Men With Classic 21-hydroxylase Deficiency
por: Will Charlton, R, et al.
Publicado: (2023)

OR19-03 Effects of Nonpeptide Orally Bioavailable ACTH Antagonists on Adrenal Gland Size and Function in Rats
por: Markison, Stacy, et al.
Publicado: (2020)

OR25-03 The Effects of Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, on Adrenal Androgens and Precursors in Patients with Classic Congenital Adrenal Hyperplasia: Results from A Multiple-Dose Phase 2 Study
por: Auchus, Richard J, et al.
Publicado: (2020)

Effects of CRN04894, a Nonpeptide Orally Bioavailable ACTH Antagonist, on Corticosterone in Rodent Models of ACTH Excess
por: Fowler, Melissa A, et al.
Publicado: (2021)

SAT-364 Nonpeptide Orally-Bioavailable ACTH Antagonists: Suppression of ACTH-Induced Corticosterone Secretion and Adrenal Hypertrophy in Rats
por: Kusnetzow, Ana, et al.
Publicado: (2019)

Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies
por: Sarafoglou, Kyriakie, et al.
Publicado: (2021)

MON-185 ACTH-Derived Peptide Antagonists as an Alternative Treatment Strategy for Congenital Adrenal Hyperplasia
por: Schubert, Tina, et al.
Publicado: (2020)

Assessment of Steroid Hormones in Both Saliva and Blood During a Phase 2 Clinical Trial for the Use of Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia
por: Keevil, Brian, et al.
Publicado: (2021)

A High-Dose Cortisol Receptor Antagonist for the Management of Severe Hyperglycemia in a Patient With an Adrenocortical Carcinoma
por: Merino, Hilda, et al.
Publicado: (2021)

PSUN11 Outcomes of Nonselective or Selective Alpha-Adrenergic Antagonist for Preoperative Management of Intra-adrenal Pheochromocytoma
por: Heckart, Jonathan, et al.
Publicado: (2022)

SUN-176 A Case of Aldosterone-Producing Adenoma with Preoperative Use of a Novel Mineralocorticoid Receptor Antagonist Esaxerenone
por: Yamanami, Hiroaki
Publicado: (2020)

OR12-2 Inhibition of Basal and ACTH-stimulated Cortisol Secretion in Humans Using an Oral Nonpeptide ACTH Antagonist (CRN04894)
por: Betz, Stephen, et al.
Publicado: (2022)

SAT-391 Perioperative Glucocorticoid Therapy for Patients with Adrenal Insufficiency: Dosing Based on Hydrocortisone Pharmacokinetic Data
por: Rahhal, Marie-Noel, et al.
Publicado: (2019)

MON-176 Discovery and Identification of Late Stage Selective Nonpeptide ACTH Antagonists for the Treatment of Cushing’s Disease, Ectopic ACTH Secreting Tumors, and Congenital Adrenal Hyperplasia
por: Kusnetzow, Ana Karin, et al.
Publicado: (2020)

SUN-214 A Novel Glucocorticoid Receptor Antagonist (CORT113176) Reveals Unique Developmental and Tissue-Specific Effects in a Neonatal Rat Model of Human Prematurity
por: Welhouse, Kyle D, et al.
Publicado: (2020)

Limited Efficacy of Mifepristone Due to Poor Tolerance: A Clinical Challenge in Managing Cortisol Excess
por: Mora Osoria, Gabriel Jose, et al.
Publicado: (2021)

Tildacerfont for the Treatment of Patients With Classic Congenital Adrenal Hyperplasia: Results From a 12-Week Phase 2 Clinical Trial in Adults With Classic CAH
por: Auchus, Richard Joseph, et al.
Publicado: (2021)

Hypercalcemia in an Infant With Pseudohypoaldosteronism Type 1
por: Jeng, Henry, et al.
Publicado: (2021)

PMON72 The "RESCUE" Trial: 11beta-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Inhibition for ACTH-Dependent Cushing's Syndrome
por: Czerwiec, Frank S, et al.
Publicado: (2022)

PSAT082 A Survey of Patients Living with CAH Assessing Their Perceptions on Glucocorticoid Regimen and Glucocorticoid-Associated Side Effects
por: Barnes, Chris, et al.
Publicado: (2022)

PSUN20 The ACSPIRE Trial: 11beta-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Inhibition for Autonomous Cortisol Secretion and Adrenal Cushing's Syndrome
por: Czerwiec, Frank S, et al.
Publicado: (2022)

MON-373 Pseudohypoaldosteronism Type 1, a Masquerader: Case Study
por: Akinseye, Leah, et al.
Publicado: (2019)

OR13-5 Bone Morphogenetic Protein-4 (BMP4) Inhibits Adrenal Cell Cortisol Synthesis by Blocking CYP17A1 and CYP11B1 Expression.
por: Garber, Scott, et al.
Publicado: (2022)

SAT-206 A Sweet and Salty Milieu: The Utility of CT in Bilateral Adrenal Hemorrhage
por: Tavares, Matthew V, et al.
Publicado: (2020)

OR29-1 Best of the Journal of the Endocrine Society: The Lateralizing Asymmetry of Adrenal Adenomas
por: Hao, Meng, et al.
Publicado: (2019)

SAT-222 Aggressive Phenotype Pheochromocytoma Associated with NF-1 and BRCA Mutation
por: Chaidarun, Tanyawan, et al.
Publicado: (2020)

ODP039 Giant Cystic Pheochromocytoma and GIST in a Patient With NF-1
por: Inkollu, Sindhura, et al.
Publicado: (2022)

OR04-1 The Developmental Origin and the Specification of the Adrenal Cortex in Humans and Cynomolgus Monkeys
por: Cheng, Keren, et al.
Publicado: (2022)

OR02-4 YAP1 Overexpression Associates With Worse Prognosis In Patients With Adrenal Tumors And YAP1 Inhibition By Verteporfin Reduces Tumorigenicity And Reverses Epithelial-mesenchymal Transition In Adrenocortical Tumor Cells
por: Bellido More, Candy, et al.
Publicado: (2019)

RF21 | PSAT100 HPA Axis Modulation by a Potent Inhibitor Indicates 11Beta-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Is a Significant Contributor to Cortisol Levels
por: Katz, David, et al.
Publicado: (2022)

SAT-227 Long-Term Outcomes of Two Siblings with X-Linked Congenital Adrenal Hypoplasia Due to a Mutation in NR0B1 (DAX1) Gene: Reproductive and Neuropsychiatric Aspects
por: Pereira, Hugo Valente do Couto, et al.
Publicado: (2020)

SUN-LB43 DLK1 Expressing Cells Contribute to the Zonation of the Adrenal Gland
por: Mariniello, Katia, et al.
Publicado: (2020)

SAT-229 Bilateral Pheochromocytoma as Incidental Finding in a Patient with Neurofibromatosis Type 1
por: Herrera, Raul A, et al.
Publicado: (2020)

MON-381 A Missed Case of Pheochromocytoma in NF1 Patient Presenting as Pre-Eclampsia
por: Williams, Kelley, et al.
Publicado: (2019)

SAT-347 Unfolding Generates an Active CYP11A1 for Mitochondrial Integration and Activity
por: Bose, Himangshu, et al.
Publicado: (2019)

SAT-354 Characterization of Cell Death Induced by SOAT1 Inhibition in Adrenocortical Carcinoma Cells
por: Weigand, Isabel, et al.
Publicado: (2019)

SUN-159 17-beta Hydroxysteroid Dehydrogenase 3 Deficiency in 1 Month Old Infant
por: Mathew, Deepa, et al.
Publicado: (2020)

SAT-165 Sterol O-Acyl Transferase 1 as a Prognostic Marker of Adrenocortical Carcinoma
por: Lacombe, Amanda Meneses Ferreira, et al.
Publicado: (2020)

SUN-210 Differentially Expressed Mirnas in Zona Reticularis (ZR) Cells of the Human Adrenal Cortex
por: Garcia, Francisco, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_te44iradovv4s6tehvsrg51es2